Open AccessN-Butyldeoxynojirimycin is a broadly effective anti-HIV therapy significantly enhanced by targeted liposome delivery
Author(s) -
Stephanie Pollock,
Raymond A. Dwek,
Dennis R. Burton,
Nicole Zitzmann
Publication year - 2008
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0b013e32830efd96
Subject(s) - liposome , infectivity , peripheral blood mononuclear cell , virology , pharmacology , viral load , ic50 , drug delivery , drug , medicine , virus , immunology , biology , in vitro , chemistry , biochemistry , organic chemistry
N-Butyldeoxynojirimycin (NB-DNJ), an inhibitor of HIV gp120 folding, was assessed as a broadly active therapy for the treatment of HIV/AIDS. Furthermore, to reduce the effective dose necessary for antiviral activity, NB-DNJ was encapsulated inside liposomes and targeted to HIV-infected cells.